Трансплантация почки и костная болезнь: факторы риска развития, диагностика
Аннотация
Заболевание костей является серьезной и часто встречающейся патологией у пациентов, перенесших трансплантацию почки. Рассмотрены разнообразные связанные с трансплантацией почки причины возникновения костных нарушений в раннем и отдаленном послеоперационном периоде: дисбаланс гормонов – фактора роста фибробластов 23, паратиреоидного гормона, витамина D, – иммуносупрессивная терапия, нарушение минерального обмена. Описан наиболее распространенный клинический вариант течения посттрансплантационной костной болезни – вторичный остеопороз, факторы риска его развития и осложнения. Анализируется диагностический алгоритм для выявления, динамического наблюдения и оценки эффективности проводимого лечения костных нарушений.
Об авторе
О. Н. Ветчинникова
ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского»
Россия
Россия
Адрес: 129110, Москва, ул. Щепкина, д. 61/2, корп. 6. Тел. (916) 532-49-00
Список литературы
1. Kalantar-Zadeh K, Molnar MZ, Kovesdy CP, Mucsi I, Bunnapradist S. Management Mineral and Bone Disorder after Kidney Transplantation. Curr. Opin. Nephrol. Hypertens. 2012; 21 (4): 389–403. PMID: 22614626. doi: 10.1097/MNH.0b013e3283546ee0.
2. Zhang R, Chouhan KK. Metabolic bone diseases in kidney transplant recipients. World J. Nephrol. 2012; 1 (5): 127–133.
3. Alshayeb HM, Josephson MA, Sprague SM. CKD – Mineral and Bone Disorder Management in Kidney Transplant Recipients. Am. J. Kidney Dis. 2013; 61 (2): 310– 325.
4. Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin. Nephrol. 2013; 33: 191–203. PMID: 23465505. doi: 10.1016/j.semnephrol.2012.12.019.
5. Kulak CAM., Borba VZC., Kulak J Júnior, Custódio MR. Bone disease after transplantation: osteoporosis and fractures risk. Arq. Bras. Endocrinol. Metab. 2014; 58 (5): 484–492. doi: 10.1590/0004-2730000003343.
6. D’Marco L, Bellasi A, Mazzaferro S, Raggi P. Vascular calcification, bone and mineral metabolism after kidney transplantation. World J. Transplant. 2015; 24; 5 (4): 222–230.
7. Heine GH, Seiler S, Fliser D. FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol. Dial. Transplant. 2012; 27: 3072–3081. doi: 10.1093/ndt/gfs259.
8. Barros X, Torregrosa JV, Martínez de Osaba MJ, Casals G, Paschoalin R, Durán CE, Campistol JM. Earlier decrease of FGF-23 and less hypophosphatemia in preemptive kidney transplant recipients. Transplantation. 2012; 94: 830–836. PMID: 23018879. doi: 10.1097/TP.0b013e318264fc08.
9. Kawarazaki H, Shibagaki Y, Fukumoto S, Kido R, Nakajima I, Fuchinoue S et al. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. Nephrol. Dial. Transplant. 2011; 26: 2691–2695. PMID: 21303965. doi: 10.1093/ndt/gfq777.
10. Sirilak S, Chatsrisak K, Ingsathit A, Kantachuvesiri S, Sumethkul V, Stitchantrakul W et al. Renal phosphate loss in long-term kidney transplantation. Clin. J. Am. Soc. Nephrol. 2012; 7: 323–331. PMID: 22134626. doi: 10.2215/ CJN.06380611.
11. Sánchez Fructuoso AI, Maestro ML, Pérez-Flores I, Valero R, Rafael S, Veganzones S et al. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients. Nephrol. Dial. Transplant. 2012; 27: 4227–4235. doi: 10.1093/ndt/gfs409.
12. Bleskestad IH, Thorsen IS, Jonsson G, Skadberg Ø, Bergrem H, Gøransson LG. Soluble Klotho and intact fibroblast growth factor 23 in long-term kidney transplant patients. Eur. J. Endocrinol. 2015; 172: 343–350. PMID: 25572388. doi: 10.1530/EJE-14-0457.
13. Rao M, Jain P, Ojo T, Surya G, Balakrishnan V. Fibroblast Growth Factor and Mineral Metabolism Parameters among Prevalent Kidney Transplant Patients. International Journal of Nephrology. 2012, Article ID 490623. doi:10.1155/2012/490623.
14. Muirhead N, Zaltman JS, Gill JS, Churchill DN, Poulin-Costello M, Mann V, Cole EH. Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice. Clin. Transplant. 2014; 28: 161–165. PMID: 24329899. doi: 10.1111/ctr.12291.
15. Wolf M, Weir MR, Kopyt N, Mannon RB, Visger JV, Deng H et al. Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation. 2016; 100 (1): 184–193. doi: 10.1097/TP.0000000000000823.
16. Perrin P, Caillard S, Javier RM, Braun L, Heibel F, Borni-Duval C et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am. J. Transplant. 2013; 13: 2653–2663. PMID: 24034142. doi: 10.1111/ajt.12425.
17. Bleskestad IH, Bergrem H, Leivestad T, Hartmann A, Gøransson LG. Parathyroid hormone and clinical outcome in kidney transplant patients with optimal transplant function. Clin. Transplant. 2014; 28: 479–486. PMID: 25649861. doi: 10.1111/ctr12341.
18. Komada H, Kakuta T, Fukagava M. Diseases of parathyroid glands in chronic kidney disease. Clin. Exp. Nephrol. 2011; 15: 797–809. doi: 10.1007/s10157-011-0502-5.
19. Jamal SA, Miller P. Secondary and Tertiary Hyperparathyroidism. J. of Clinical Densitometry: Assessment of Skeletal Health. 2013; 16 (1): 64–68. http://dx.doi.org/10.1016/j.jocd.2012.11.012.
20. Amin T, Coates TP, Barbara J, Hakendorf P, Karim N. Prevalence of Hypercalcaemia in a Renal Transplant Population: A Single Centre Study. Int. J. Nephrology. 2016; Article ID 7126290, 5 pages. http://dx.doi.org/10.1155/2016/7126290.
21. Tillmann F-P, Wächtler C, Hansen A, Rump LC, Quack I. Vitamin D and cinacalcet administration pretransplantation predict hypercalcaemic hyperparathyroidism post- transplantation: a case-control study of 355 deceased-donor renal transplant recipients over 3 years. Transplantation Research. 2014; 3: 21–26. doi: 10.1186/s13737-014-0021-5.
22. Dewberry LC, Tata S, Graves S, Weber CJ, Sharma J. Predictors of tertiary hyperparathyroidism: Who will benefit from parathyroidectomy? Surgery. 2014; 156: 1631–1636; discussion 1636–1637. PMID: 25456966. doi: 10.1016/j.surg.2014.08.070.
23. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al. Endocrine Society. Evolution, treatment and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011; 96: 1911–
24. http://dx.doi.org/10.1210/jc.2011-0385.
25. Bienaimé F, Girard D, Anglicheau D, Canaud G, Souberbielle JC, Kreis H et al. Vitamin D status and outcomes after renal transplantation. J. Am. Soc. Nephrol. 2013; 24: 831– 841. PMID: 23539758. doi: 10.1681/ASN.2012060614.
26. Keyzer CA, Riphagen IJ, Joosten MM, Navis G, Muller Kobold AC, Kema IP et al. Associations of 25(OH) and 1,25(OH)2 vitamin D with long-term outcomes in stable renal transplant recipients. J. Clin. Endocrinol. Metab. 2015; 100: 81–89. PMID: 25361179. doi: 10.1210/jc.2014-3012.
27. Penny H, Frame S, Dickinson F, Garrett G, Young AR, Sarkany R et al. Determinants of vitamin D status in long-term renal transplant patients. Clin. Transplant. 2012; 26: E617– E623. PMID: 23083399. doi: 10.1111/ctr.12039.
28. Beique LC, Kline GA, Dalton B, Duggan K, Yilmaz S. Predicting deficiency of vitamin D in renal transplant recipients in northern climates. Transplantation. 2013; 95: 1479–1484. doi: 10.1097/TP.0b013e31828eea93.
29. Eyal O, Aharon M, Safadi R, Elhalel MD. Serum vitamin D levels in kidney transplant recipients: the importance of an immunosuppression regimen and sun exposure. Isr. Med. Assoc. J. 2013; 15: 628–633. PMID:24266090.
30. Kulshrestha S, Ojo AO, Luan FL. Metabolic syndrome, vitamin D deficiency and hypoadiponectinemia among nondiabetic patients early after kidney transplantation. Am. J. Nephrol. 2013; 37: 399–404. doi: 10.1159/000349930.
31. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinology and Metabolism Clinics of North America. 2012; 41 (3): 595–611.
32. Henneicke H, Gasparini SJ, Brennan-Speranza TC, Zhou H, Seibel MJ. Glucocorticoids and bone: local effects and systemic implications. Trends in Endocrinology and Metabolism. 2014; 25 (4): 197–211.
33. Clarke BL. Corticosteroid-induced osteoporosis: an update for dermatologists. American Journal of Clinical Dermatology. 2012; 13 (3): 167–190.
34. Rossini M, Orsolini G, Viapiana O, Adami S, Gatti D. Bisphosphonates in the treatment of glucocorticoidinduced osteoporosis: pros. Endocrine. 2015; 49 (3): 620–627.
35. Liou SF, Hsu JH, Chu HC, Lin HH, Chen IJ, Yeh JL. KMUP-1 promotes osteoblast differentiation through cAMP and cGMP pathways and signaling of BMP-2/ Smad1/5/8 andWnt/β-catenin. Journal of Cellular Physiology. 2015; 230 (9): 2038–2048.
36. Moutsatsou P, Kassi E, Papavassiliou AG. Glucocorticoid receptor signaling in bone cells. Trends in Molecular Medicine. 2012; 18 (6): 348–359.
37. Chen F, Zhang L, OuYang Y, Guan H, Liu Q, Ni B. Glucocorticoid induced osteoblast apoptosis by increasing E4BP4 expression via up-regulation of Bim. Calcified Tissue International. 2014; 94 (6): 640–647.
38. Naves MA, Pereira RMR, Comodo AN, de Alvarenga ELFC, Caparbo VF, Teixeira VPC. Effect of dexamethasone on human osteoblasts in culture: involvement of β1 integrin and integrin-linked kinase. Cell Biology International. 2011; 35 (11): 1147–1151.
39. Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nature Reviews Endocrinology. 2015; 9 (5): 265–276.
40. Manolagas SC. Steroids and osteoporosis: the quest for mechanisms. Journal of Clinical Investigation. 2013; 123 (5): 1919–1921.
41. Westenfeld R, Schlieper G, Wöltje M, Gawlik A, Brandenburg V, Rutkowski P. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis – implications for post-transplantation bone disease. Nephrol. Dial. Transplant. 2011; 26: 4115–4123. doi: 10.1093/ndt/gfr214.
42. Ветчинникова ОН, Шестеро ЕВ, Егорова ЕА. Минерально-костные нарушения у реципиентов почечного трансплантата. Нефрология. 2016; 20 (6): 49–56. Vetchinnikova ON, Shestero EV, Еgorova EA. Mineral and Bone Disorder in Renal Transplant Recipients. Nefrologiya = Russian journal of nephrology. 2016; 20 (6): 49–56 [English abstract].
43. Tomida K, Hamano T, Ichimaru N, Fujii N, Matsui I, Nonomura N et al. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic- phase phosphate wasting after renal transplantation. Bone. 2012; 51: 729–736. PMID: 2
44. PMID: 2796419. doi: 10.1016/j.bone.2012.06.027.
45. Gupta AK, Huang M, Ramesh Prasad GV. Determinants of bone mineral density in stable kidney transplant recipients. Journal of Nephrology. 2012; 25 (3): 373–383.
46. Molnar MZ, Naser MS, Rhee CM, Kalantar-Zadeh K, Bunnapradist S. Bone and mineral disorders after kidney transplantation: therapeutic strategies. Transplantation Reviews. 2014; 28 (2): 56–62.
47. Sukumaran Nair S, Lenihan CR, Montez-Rath ME, Lowenberg DW, Chertow GM, Winkelmayer WC. Temporal trends in the incidence, treatment and outcomes of hip fracture after first kidney transplantation in the United States. American Journal of Transplantation. 2014; 14 (4): 943–951.
48. Naylor KL, Li FH, Lam NN, Hodsman AB, Jamal SA, Garg AX. Fracture risk in kidney transplant recipients: a systematic review. Transplantation. 2013; 95 (12): 1461–1470.
49. Gurin L, Gohh R, Evangelista P. Pain syndrome with stress fractures in transplanted patients treated with calcineurin inhibitors. Clin. Kidney. J. 2012; 5: 13–16. doi: 10.1093/ndtplus/sfr156.
50. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl. 2009; 113: S1–S130. PMID: 19644521. doi: 10.1038/ki.2009.188.
51. Ермоленко ВМ, Волгина ГВ, Михайлова НА, Земченков АЮ, Ряснянский ВЮ, Ветчинникова ОН и др. Лечение минеральных и костных нарушений при хронической болезни почек. Нефрология. Клинические рекомендации. Ред.: Е.М. Шилов, А.В. Смирнов, Н.Л. Козловская. М.: ГЭОТАР-Медиа, 2016: 687–709. Ermolenko VM, Volgina GV, Mikhailova NA, Zemchenkov AYu, Ryasnyanskii VYu, Vetchinnikova ON i dr. Lechenie mineral`nikh i kostnikh narusheniy pri khronicheskoy bolezni pochek. Nefrologija. Klinicheskie rekomendacii. Red.: E.M. Shilov, A.V. Smirnov, N.L. Kozlovskaja. M.: GEOTAR-Media, 2016: 687–709.
52. Ketteler M, Elder GJ, Evenepoel P, Ix JH, Jamal SA, Lafage-Proust M-H et al. Revisiting KDIGO clinical practice guideline on chronic kidney disease mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int. 2015; 87: 502–528.
53. Naylor KL, Zou G, Leslie WD, McArthur E, Lam NN, Knoll GA et al. Frequency of bone mineral density testing in adult kidney transplant recipients from Ontario, Canada: a population-based cohort study. Canadian Journal of Kidney Health and Disease. 2016; 3: 2–9. doi: 10.1186/s40697-016-0092-y.
54. Naylor KL, Jamal SA, Zou GY, McArthur E, Lam NN, Leslie WD et al. Fracture incidence in adult kidney transplant recipients. Transplantation. 2015; 100 (1): 167–175.
55. Nishiyama KK, Pauchard Y, Nikkel LE, Iyer S, Zhang C, McMahon DJ et al. Longitudinal HR‐pQCT and Image Registration Detects Endocortical Bone Loss in Kidney Transplantation Patients. Journal of Bone and Mineral Research. 2015; 30 (3): 554–561.
Рецензия
Для цитирования:
Ветчинникова О.Н. Трансплантация почки и костная болезнь: факторы риска развития, диагностика. Вестник трансплантологии и искусственных органов. 2017;19(1):111-121. https://doi.org/10.15825/1995-1191-2017-1-111-121
For citation:
Vetchinnikova O.N. Kidney transplantation and bone disease: risk factors of development and diagnostics. Russian Journal of Transplantology and Artificial Organs. 2017;19(1):111-121. (In Russ.) https://doi.org/10.15825/1995-1191-2017-1-111-121
Просмотров: 3248
Послать статью по эл. почте 